Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Hum Genet. Author manuscript; available in PMC 2012 July 1.
Published in final edited form as:
Published online 2011 November 17. doi:  10.1038/jhg.2011.123
PMCID: PMC3266441

Functional Analysis of APOE Locus Genetic Variation Implicates Regional Enhancers in the Regulation of Both TOMM40 and APOE


Genetic variation within the apolipoprotein E gene (APOE) locus is associated with late-onset Alzheimer's disease risk and quantitative traits as well as apoE expression in multiple tissues. The aim of this investigation was to explore the influence of APOE locus cis-regulatory element enhancer region genetic variation on regional gene promoter activity. Luciferase reporter constructs containing haplotypes of APOE locus gene promoters; APOE, APOC1, and TOMM40, and regional putative enhancers; TOMM40 IVS2-4, TOMM40 IVS6 poly-T, as well as previously described enhancers; ME1, or BCR, were evaluated for their effects on luciferase activity in 3 human cell lines. Results of this investigation demonstrate that in SHSY5Y cells, the APOE promoter is significantly influenced by the TOMM40 IVS2-4 and ME1 and the TOMM40 promoter is significantly influenced by the TOMM40 IVS6 poly-T, ME1 and BCR. In HepG2 cells, theTOMM40 promoter is significantly influenced by all four enhancers, whereas the APOE promoter is not influenced by any of the enhancers. The main novel finding of this investigation was that multiple APOE locus cis-elements influence both APOE and TOMM40 promoter activity according to haplotype and cell type suggesting that a complex transcriptional regulatory structure modulates regional expression.

Keywords: APOE, TOMM40, APOC1, ME1, BCR, Regulation, Enhancer, Luciferase Reporter Assay


Multiple genetic variations within the APOE locus are strongly associated with late-onset Alzheimer's disease (LOAD) risk. 1 The ε4 allele of APOE is the strongest known genetic risk factor for LOAD. 2-4 However, inheritance of the APOE ε4 is neither necessary nor sufficient to cause the disease, 5, 6 and the mechanism by which the ε4 allele functionally influences the risk and progression of LOAD remains unknown.

Other genetic elements in the APOE locus, such as APOE promoter polymorphisms, have been reported to be associated with LOAD, including SNPs in position -491, -427, -219 (Th1/E47cs), and +113 as well as gene expression. 7-11 Thus, it has been postulated that expression levels of the APOE gene product can also contribute to LOAD risk. In addition to the APOE promoter, other cis-regulatory elements of APOE have been characterized, which include multienhancer 1 (ME1), that influences APOE regulation in macrophages and adipocytes, 12, 13 and a brain control region (BCR) that can modulate APOE expression in neurons and microglial. 14

SNPs within the TOMM40 gene have robustly shown association with LOAD in multiple genome-wide association studies (GWAS). 15-18 The TOMM40 SNP, rs2075650, located within the intervening sequence (IVS) 2, has been associated with both LOAD risk 17, 19 and quantitative traits, 20-23 such as age-at-onset and Aβ42 levels, suggesting that the TOMM40 region contributes to LOAD phenotypes. Our recent study has reported that IVS 2 SNPs within the TOMM40 gene, as well as other SNPs both proximal and distal to APOE, are associated with CSF apoE levels 24 and PMB apoE expression in AD hippocampus. 25 Recently it has been reported that a poly-T polymorphism (rs10524523) within IVS 6 of TOMM40 is associated with LOAD age-at-onset. 26

A report on APOE locus linkage disequilibrium (LD) patterns suggests that strong LD with APOE ε4 exists both proximal, (in a region partially spanning the TOMM40 gene), and distal to APOE, (in the ME1 region). 4 Interestingly, the association between TOMM40 and LOAD risk is not fully explained by LD between TOMM40 SNPs and the APOE SNP (rs429358) that defines ε4 status suggesting that other APOE locus SNPs contribute to this association with LOAD. 4

Given that multiple SNPs spanning a large region at the APOE locus are associated with LOAD risk, LOAD specific quantitative traits, age-at-onset, LD and apoE expression levels, we hypothesized that a unique haplotype structure functionally influences the expression of multiple genes at the APOE locus. Thus, the aim of this investigation was to demonstrate that promoter activity of three APOE locus genes (TOMM40, APOE, APOC1) are influenced by previously described regulatory element enhancers (ME1, BCR) and putative regulatory element enhancers (TOMM40 IVS2-4, TOMM40 IVS6 Poly-T) differentially according to haplotype.

The main, novel finding of this investigation was that genomic regions within TOMM40 influence both TOMM40 and APOE but not APOC1 promoter activity, suggesting that these two genes may be co-regulated. Furthermore, APOE locus enhancers influence both TOMM40 and APOE promoters according to haplotype and cell type, implicating a complex system of gene regulation that is specific to genetic content and cellular microenvironment.

Materials and Methods

APOE Locus LD Structure and Trans-acting Factor Site Prediction

The pattern of pairwise LD was measured for the APOE locus by D' metrics of chromosome 19: 50080-50150 kb. Haplotypes were constructed using the algorithm implemented in Haploview (version 4.2) for SNPs available with a MAF ≥ 0.01 for the Haploview Caucasian of Northern and Western European descent sample (CEU) 27 (Figure 1).

Figure 1
APOE Locus Linkage Disequilibrium Plot

Trans-acting factor sites were predicted for APOE locus promoters and enhancers using UCSC human genome browser ENCODE data for histone marker sites and DNase I hypersensitivity sites 28, 29 (Figure 2).

Figure 2
APOE Locus Putative Promoter-Enhancer Regions

Generation of Regulatory Haplotype Reporters

Genomic DNA (gDNA) was obtained from the University of Washington (UW) Alzheimer's Disease Research Center after approval by the human subject Institutional Review Boards of UW and Veterans Affairs Puget Health Care System. Our regions of interest were PCR amplified and DNA sequenced from gDNA of 32 Caucasian subjects. See supplement for list of primer sequences. Two to three haplotypes for each regulatory genetic region of interest were chosen according to sequenced SNP content and SNP frequency (Table 1). Variants of TOMM40, APOE or APOC1 promoter core region haplotypes were inserted 5′ to the luciferase gene of the pGL4.10[luc2] vector (Promega) to produce promoter only constructs. To produce promoter-enhancer constructs, haplotype variants of TOMM40 IVS2-4, TOMM40 IVS6 poly-T, ME1 or BCR genomic regions were inserted into the promoter constructs 3′ to the luciferase gene. The In-Fusion® PCR Cloning System (Clontech) was used for all the cloning procedures. After propagating the recombinant DNA in E. coli host cell, the reporter constructs were isolated and purified by ion-exchange column (Qiagen). Inserts of all constructs were fully DNA-sequenced to validate the correct genetic contents.

Table 1
APOE Locus Haplotype Description

Cell Culture

Human neuroblastoma SHSY5Y cells (ATCC) were grown in 44.5% Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY) with 44.5% F12 (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin/streptomycin (100 μU/ml penicillin, and 100 μg/ml streptomycin) at 37°C in a 5% CO2 atmosphere. Human hepatocytoma HepG2 cells (ATCC) and U118 astrocytoma cells (ATCC) were grown in 89% DMEM (Gibco), 10% fetal bovine serum (Gibco), and 1% penicillin/streptomycin (100 μU/ml penicillin, and 100 μg/ml streptomycin) at 37°C in a 5% CO2 atmosphere. Cells were passaged at 5 × 104 per well into 96-well tissue culture plates 48 hours prior to transfection.

Luciferase Reporter Construct Transfection and Assay

SHSY5Y and HepG2 cells were transiently transfected for 48 hours with promoter-enhancer reporter constructs using Lipofectamine 2000 (Invitrogen), according to manufacturer instructions. All transfection assays included a TOMM40, APOE and APOC1 promoter only (no enhancer) luciferase pGL4.10[luc2] haplotype reporter constructs as basal expression controls and promoter-less luciferase pGL4.10[luc2] as a negative control. In addition, the renilla pGL4.75[hRluc/CMV] was co-transfected as an internal control. All transfection assays included duplicate construct transfections and transfection assays were performed in triplicate. Failed transfection reactions were duplicated, leading to 6 – 8 replicate transfections for each haplotype reporter construct.

SHSY5Y, HepG2 and U118 transiently transfected cells were harvested after 48 hours using the Dual Glo ™ Luciferase Assay System (Promega) which allows for high throughput analysis of firefly luciferase (pGL4.10[luc2] constructs in the first step. In the second step, after quenching the firefly luminescence and activating the renilla luciferase (pGL4.75[hRluc/CMV), luminescence from the internal control was analyzed. Luciferase luminescent counts per second (CPS) were measured using a Wallac Victor2 1420 Multilabel Counter.

Relative Quantitation of Haplotypes Expression Levels and Statistical Analysis

To measure the enhancer effect on promoter activity, luciferase activities of promoter-only constructs served as base-line controls (set at 1.0), and were compared to promoter-enhancer constructs. First, a ratio of F/R CPS was calculated as firefly (F) luciferase construct CPS per renilla (R) luciferase internal control CPS for each transfected construct, per manufacturers instructions (Dual Glo ™ Luciferase Assay System, Promega). Haplotype expression levels relative to promoter was calculated for each promoter-enhancer reporter construct (i.e. F/R APOE-promoter haplotype 1- ME1 haplotype 2 / F/R APOE-promoter haplotype 1). This data was then analyzed using an ANOVA to compare haplotypes (SPSS version 13). All statistical tests within specific promoter-enhancer haplotype groups were computed by Bonferroni correction for multiple comparisons.


The APOE Locus

To evaluate the LD structure of the 64 kb APOE locus, SNPs spanning from the TOMM40 5′ region to the BCR were analyzed using Haploview. 27 The promoter and enhancer regions of interest in this investigation; TOMM40, APOE and APOC1 promoter regions, ME1and BCR regulatory element enhancers, TOMM40 IVS2-4, TOMM40 IVS6 Poly-T putative regulatory element enhancers, are either in strong or moderate LD with each other or in the case of the BCR, are not in LD with other selected genetic elements (Figure 1). Except for the TOMM40 IVS6 poly-T, all the promoter and enhancer regions of interest are consistently overlapped with the ENCODE tracks in the UCSC human genome browser. 28, 29 These ENCODE tracks include DNase I hypersensitivity sites, histone mark H3K4Me3 sites for promoter and H3K4Me1 sites for enhancers (Figure 2, Panel A).

Putative regulatory haplotype content was identified by SNP genotyping of human subjects and amplified from subject genomic DNA. Putative regulatory haplotype variants were then verified by sequencing and cloned into the luciferase reporter constructs as shown in Figure 2, Panel B. Thus, a large panel of luciferase reporter clones were generated that included eight promoter-only constructs (three promoters with a total of eight variants, Table 1) and 80 promoter-enhancer haplotype constructs (8 promoter haplotypes plus 10 enhancer haplotypes; Table 1). Luciferase gene activities of reporter constructs were measured in the three human cell lines that included a neuronal cell line (SHSY5Y), a hepatocyte cell line (HepG2) and an astrocyte cell line (U118). No statistically significant differences were observed among APOC1 promoter-enhancer haplotypes (data not shown). In contrast, statistically significant differences in luciferase gene expression were observed for TOMM40 and APOE promoter-enhancer haplotypes in both SHSY5Y and HepG2 cells, but not U118 cells (Figure 3).

Figure 3
Cell type (SHSY5Y, HepG2, U118) specific expression of TOMM40 and APOE regulatory haplotypes. ANOVA p-values (includes Bonferroni multiple comparison correction) representing the difference between haplotypes are presented for transfection replicates ...

Haplotypes Expression Levels in SHSY5Y Cells

Significant differences in luciferase gene expression were found among two APOE promoter-enhancer haplotypes and three TOMM40 promoter-enhancer haplotypes in the SHSY5Y human neuronal cell line (Figure 3, Figure 4).

Figure 4
Effect of APOE and TOMM40 Promoter Haplotype on Promoter - Enhancer Regulatory Haplotype Expression

A total of six APOE promoter-TOMM40 IVS2-4 haplotype variants were tested and compared to their promoter-only counterparts. Significant differences in luciferase gene expression were found between four haplotype pairs (Figure 4, Panel A; significant levels relative to 1.0 as noted with asterisk). These differences were not observed for similar TOMM40 promoter haplotypes expressed in SHSY5Y cells, indicating that an enhancer/silencer effect of this TOMM40 IVS2-4 region is specific to the APOE promoter in SHSY5Y cells (Figure 4).

A total of nine APOE promoter-ME1 haplotypes were tested. Expression levels of APOE promoter-ME1 haplotypes were higher than the APOE promoter-only construct, where one haplotype (APOE promoter 2-ME1-1) showed significantly higher expression (Figure 4, Panel B; significant levels above 1.0 noted with asterisk). We also tested nine TOMM40 promoter- ME1 haplotype variants. Significant differences in luciferase gene expression were observed in this setting where the TOMM40 promoter 1-related haplotypes have higher expression levels than the other haplotypes (Figure 4, Panel D). All TOMM40 promoter-ME1 haplotypes levels were lower than the TOMM40 promoter-only construct (levels below 1.0; significantly lower levels are noted with asterisks). These results confirm the previously described enhancer activity of ME1 on APOE promoter activity 12, 13 and suggest an opposite silencer effect of ME1 on TOMM40 promoter activity.

A total of nine TOMM40 promoter-IVS6 poly-T haplotype variants were tested. The expression level of TOMM40 promoter 1-IVS6 16T haplotype was significantly higher than other haplotypes (Figure 4, Panel C). Six TOMM40 IVS6 poly-T haplotypes had significantly lower expression levels compared to the TOMM40 promoter-only construct (asterisk). These results suggest that the TOMM40 IVS6 poly-T (or rs10524523) locus has measurable enhancer/silencer activity and that the direction of its effect depends on the specific haplotype content of theTOMM40 promoter (Figure 4, Panel C).

A total of six TOMM40 promoter-BCR enhancer haplotype variants were tested. Significant differences were found between the TOMM40 promoter 1-BCR-1 haplotype and the other haplotypes (Figure 4, Panel E). The majority of TOMM40 promoter-BCR haplotypes showed significantly lower expression levels compared to the TOMM40 promoter-only construct (significant levels below one noted with asterisk) suggesting a silencer effect of BCR on the TOMM40 promoter in SHSY5Y cells. (Figure 4, Panel E).

Haplotypes Expression Levels in HepG2 Cells

Expression levels of the same eight promoter-only constructs and 80 promoter-enhancer haplotype constructs were also tested in the HepG2 human neuronal cell line (Table 1). Significant differences were found among three separate TOMM40 promoter-enhancer haplotypes, differences which were not observed among APOE promoter-enhancer haplotypes (Figure 3, Figure 4).

Among the six haplotype variants of TOMM40 promoter-TOMM40 IVS2-4, significant expression differences in HepG2 cells were found between theTOMM40 promoter 1-TOMM40 IVS2-4-2 haplotype and two other TOMM40 promoter-TOMM40 IVS2-4 haplotypes. All TOMM40 promoter-TOMM40 IVS2-4 haplotypes, except TOMM40 promoter 1-TOMM40 IVS2-4-2, have significantly lower expression levels relative toTOMM40 promoter-only construct (asterisk) suggesting that TOMM40 IVS2-4 has a silencer effect in HepG2 cells (Figure 4, Panel F).

Significant differences in expression levels in HepG2 cells were also found between TOMM40 promoter-ME1 haplotype variants. All TOMM40 promoter 1-ME1 haplotype levels were lower than the TOMM40 promoter-only counterpart in HepG2 cells (asterisks) suggesting a silencer effect that is significantly lower for the TOMM40 promoter 1 – ME1-1 and TOMM40 promoter 2-ME1-1 haplotypes compared to the TOMM40 promoter 3 – ME1-1 haplotype (Figure 4, Panel G).

Significant differences in expression levels in HepG2 cells were found between multipleTOMM40 promoter-BCR haplotypes (Figure 4, Panel H). All TOMM40 promoter-BCR haplotypes have significantly lower expression compared to the TOMM40 promoter-only construct in HepG2 cells (asterisk) suggesting a silencer effect HepG2 cells that is significantly lower for the BCR-2 haplotype compared to the BCR-1 haplotype (Figure 4, Panel H).


The core region of APOE locus consists of a large haplotype block that contains several genes, including TOMM40, APOE and APOC1 (Figure 1). 4 Genetic markers in all three genes have consistently been shown to be associated with LOAD in multiple studies. 2-4 Current consent is that the ε4 allele of APOE is the only true effector of LOAD, and positive association signals of other markers are merely the effect of LD with the ε4 allele. The TOMM40 gene contains a poly-T repeat within intron 6 (TOMM40 IVS6 poly-T rs10524523) that has been recently reported to be associated with AD age-at-onset, 26 and SNPs in the TOMM40 intron 2 – 4 region (TOMM40 IVS2-4) are consistently associated with LOAD risk, quantitative trait loci, 20-23 and apoE expression levels. 24, 25 In addition, the association between TOMM40 SNPs and LOAD cannot be fully explained by LD betweenTOMM40 SNPs and APOE ε4 alone 4 and APOE locus enhancers, ME1 and BCR are associated with expression levels. 12-14 However, the functional influence of genetic variation within APOE locus enhancers has not been previously characterized. In this investigation, we hypothesized that promoter activity of three APOE locus genes (TOMM40, APOE, APOC1) are functionally influenced by genetic variation within previously described regulatory elements (ME1, BCR) and putative regulatory elements (TOMM40 IVS2-4,TOMM40 IVS6 Poly-T) differentially according to haplotype. The main novel finding was that enhancers within TOMM40 influence both TOMM40 and APOE promoter activity in a haplotype and cell-type-specific manner.

Significant differences in reporter assay expression levels were found in 3 TOMM40 promoter-enhancer and 2 APOE promoter-enhancer haplotype variants in SHSY5Y neuronal cells (Figure 3, Figure 4). Significant differences were also found in 3 different TOMM40 promoter- enhancer haplotypes in HepG2 hepatocyte cell line (Figure 3, Figure 4). However, no significant differences were found in all APOC1 promoter- enhancer haplotypes and all promoter-enhancer haplotypes transfected into U118 astrocyte cells (Figure 3). Specifically, the TOMM40 promoter 1 -TOMM40 IVS6 16T haplotype showed increased expression in the SHSY5Y neuronal cell line compared to 6 other haplotype variant counterparts (Figure 4, Panel C). Interestingly, 6 TOMM40 IVS6 poly-T haplotypes (asterisks) had significantly lower expression levels compared to the TOMM40 promoter haplotype alone (levels below one) implicating TOMM40 promoter activity inhibition by allTOMM40 IVS6 poly T haplotypes except the TOMM40 promoter 1 -TOMM40 IVS6 poly-T 16T haplotype (Figure 4, Panel C). There was no significant difference between APOE promoter - TOMM40 IVS6 poly-T or APOC1 promoter -TOMM40 IVS6 poly-T haplotypes in any of the cell types tested, which suggests that theTOMM40 IVS6 poly-T 16T haplotype impacts TOMM40 expression, but not APOE or APOC1 expression. However, since others have reported promoter activity outside of the APOE core promoter sequence used in the present study, 8, 30 the possibility remains that the TOMM40 IVS6 poly-T haplotype influences the APOE promoter outside of the core promoter region tested in this study.

The TOMM40 IVS6 poly-T haplotype specific expression was only significant in the neuronal SHSY5Y cell line, not HepG2 or U118 cell lines, suggesting that this haplotype may be particularly important in neurons. Interestingly, the TOMM40 IVS6 poly-T 16T haplotype contains a short version of poly-T repeat that has recently been associated with a later AD age-at-onset. 26 This LOAD association, together with our result of higher haplotype expression, suggests that the short version (16T) of TOMM40 IVS6 poly-T combined with a specific TOMM40 promoter haplotype may be a modifier of AD risk through increased TOMM40 expression not APOE expression.

All 3 of the TOMM40 promoter 1 – ME1 haplotypes showed significant differences compared to otherTOMM40 promoter – ME1 haplotypes in SHSY5Y cells (Figure 4, Panel D). In contrast, this TOMM40 promoter 1 pattern was not seen in HepG2 cells the most significant increase in expression was seen between TOMM40 promoter 3 – ME1-1 and the other TOMM40 promoter haplotypes, indicating a cell type specific expression pattern for ME1 that is also haplotype-specific (Figure 4, Panel G). In addition, the APOE promoter 2 – ME1-1 haplotype showed a marginally significant increase in expression (Figure 3 and Figure 4, Panel B). This is consistent with previous reports of increased expression in the presence of a ME1 transgene 12, 13, 31 and is a novel finding in that genetic variation within ME1 can further modulate expression levels. There was no increased expression of the ME1 haplotypes in the U118 astrocyte cell line, which is in contrast to a previous report that shows apoE expression is increased in transgenic APOE-ME1 mouse astrocytes in the brain. 31 It can be speculated that this inconsistency is due to either human verses mouse or in vitro verse in vivo differences between studies. But, also, since none of the reporter constructs showed significant differences in the U118 astrocyte cell line, it may represent a lack of APOE locus regulatory element activity in this cell line. The APOE promoter-ME1 showed marginally significant differences between haplotypes in SHSY5Y cells, but differences did not remain significant after correction of multiple comparisons (Figure 3, Figure 4; Panel B). However, most APOE promoter – ME1 haplotype expression was increased above the APOE promoter-only baseline of 1.0, significantly APOE promoter 2 – ME1-1, suggesting that ME1 has a general enhancing effect on APOE promoter activity. Notably, all TOMM40 promoter 1-ME1 haplotype levels were lower than the TOMM40 promoter-only haplotypes in both SHSY5Y neuronal cells and HepG2 cells (Figure 4, Panel D and Panel G; levels below 1.0; significantly lower levels are noted with asterisks). The TOMM40 promoter – ME1 results suggests that ME1 inhibits TOMM40 expression in contrast to enhancing APOE expression.

The TOMM40 promoter is influenced by the silencer effect of BCR in both SHSY5Y and HepG2 cells (Figure 4, Panel E: Figure 4, Panel H). All TOMM40 promoter-BCR haplotypes have significantly lower expression compared to the TOMM40 promoter-only haplotypes (significant levels below 1 noted with asterisk) in both HepG2 cells (Figure 4, Panel H) and SHSY5Y cells (Figure 4, Panel E) except the TOMM40 promoter 1-BCR-1 haplotype in SHSY5Y cells (Figure 4, Panel E). Moreover, in HepG2 cells the difference in expression between the BCR-1 and BCR-2 haplotype is significant regardless of the TOMM40 promoter haplotype, hinting that genetic variation in BCR may influence TOMM40 expression according to cell type and remain independent of TOMM40 promoter haplotype. Furthermore, the lack of influence by the BCR on the APOE promoter haplotypes in HepG2 cells is consistent with a previous report describing apoE expression in mice expressing apoE and BCR transgenes as constrained to the brain and not present in the liver. 14 Why BCR reportedly influences brain apoE levels 14 and not the APOE promoter haplotypes in SHSY5Y neuronal cells remains to be determined.

The APOE promoter 2 haplotype is significantly influenced by the TOMM40 IVS2-4-2 haplotype with increased expression compared to the other TOMM40 IVS2-4 haplotypes in SHSY5Y cells (Figure 4, Panel A). These results are consistent with results from previous studies where similar genetic variation within TOMM40 IVS2-4 (i.e. rs59007384 G allele) is associated with higher CSF and PMB apoE expression. 24, 25 The TOMM40 promoter-1 haplotype is also influenced by the TOMM40 IVS2-4-2 haplotype, showing higher expression compared to other haplotypes in HepG2 cells (Figure 4, Panel F). These results suggest that genetic variation within the TOMM40 IVS2-4 region impacts expression of APOE locus genes in a cell type specific manner. Interestingly, a SNP (rs2075650) within the TOMM40 IVS2-4 region is highly significantly associated with AD quantitative traits, such as Aβ42, in GWAS 20-23,32 as well as survival into old age, further implicating the TOMM40 IVS2-4 region in a biological effect.

Evidence presented here implicates APOE locus genetic variation within regional enhancers as contributors to regional promoter activity. These results are further supported by ENCODE data that shows promoter (H3K4Me3) and enhancer (H3K4Me1) associated histone marks overlap with the regulatory haplotype reporter construct sites presented here (Figure 2). 28, 29 In addition, ENCODE DNase1 hypersensitivity cluster results overlap with regulatory haplotype region reporter construct sites, suggesting trans-acting factor binding at these APOE locus regulatory haplotype regions (Figure 2). 28, 29 Thus, it may be further speculated that both TOMM40 and APOE expression are influenced by regional regulatory haplotypes that in turn biologically impact AD pathogenesis.

In conclusion, functional characterization of APOE locus haplotype expression suggests that a complex transcriptional regulatory structure is modulated by distinct haplotypes composed of multiple, distantly located SNPs. The main novel finding of this investigation is that regions within TOMM40 influence both TOMM40 and APOE promoter activity in vitro depending on haplotype and cell type. These TOMM40 regions include a recently described poly-T in intron 6 that is associated with AD age-at-onset, 26 and an intron 2 – 4 region that has been associated with AD risk 19, 33 and AD quantitative traits in multiple GWAS. 20-23 This functional study suggests that non-APOE ε4 allele SNPs contribute to a promoter-enhancer haplotype structure that influences both TOMM40 and APOE gene regulation suggesting that the genetic association between AD and TOMM40, found in multiple genetic studies, may be due to an AD modifier effect by TOMM40 that is haplotype and cell type specific.


This work was supported in part by the U.S. Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program, and National Institutes of Health/National Institutes on Aging grant 1K99AG034214-01A1. We thank J. Anthony Gill for the editing of the manuscript.


1. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213–227. [PMC free article] [PubMed]
2. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644–5651. Epub 2006 Mar 5627. [PubMed]
3. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68:613–618. [PubMed]
4. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89:655–665. Epub 2007 Apr 2016. [PMC free article] [PubMed]
5. Hyman BT, Gomez-Isla T, Rebeck GW, Briggs M, Chung H, West HL, et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci. 1996;802:1–5. [PubMed]
6. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol. 2004;61:1930–1934. [PubMed]
7. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998;18:69–71. [PubMed]
8. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998;421:105–108. [PubMed]
9. Ramos MC, Matias S, Artiga MJ, Pozueta J, Sastre I, Valdivieso F, et al. Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter. Neuroreport. 2005;16:1027–1030. [PubMed]
10. Town T, Paris D, Fallin D, Duara R, Barker W, Gold M, et al. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998;252:95–98. [PubMed]
11. Parker GR, Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE. Apolipoprotein gene E4 allele promoter polymorphisms as risk factors for Alzheimer's disease. Psychiatr Genet. 2005;15:271–275. [PubMed]
12. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem. 2000;275:31567–31572. [PubMed]
13. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem. 2002;277:31900–31908. Epub 32002 May 31924. [PubMed]
14. Zheng P, Pennacchio LA, Le Goff W, Rubin EM, Smith JD. Identification of a novel enhancer of brain expression near the apoE gene cluster by comparative genomics. Biochim Biophys Acta. 2004;1676:41–50. [PubMed]
15. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet. 2007;16:865–873. [PubMed]
16. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41:192–198. [PMC free article] [PubMed]
17. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088–1093. [PMC free article] [PubMed]
18. Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010;15:756–766. [PubMed]
19. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–1840. [PMC free article] [PubMed]
20. Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS ONE. 2009;4:e6501. [PMC free article] [PubMed]
21. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage. 2010;53:1051–1063. [PMC free article] [PubMed]
22. Han MR, Schellenberg GD, Wang LS. Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010;10:90. [PMC free article] [PubMed]
23. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011;76:69–79. [PMC free article] [PubMed]
24. Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis. 2008;13:255–266. [PMC free article] [PubMed]
25. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:409–417. [PMC free article] [PubMed]
26. Roses AD. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol. 2010;67:536–541. [PMC free article] [PubMed]
27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265. [PubMed]
28. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006. [PubMed]
29. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, et al. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res. 2010;38:D620–625. [PMC free article] [PubMed]
30. Paik YK, Chang DJ, Reardon CA, Walker MD, Taxman E, Taylor JM. Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J Biol Chem. 1988;263:13340–13349. [PubMed]
31. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 2001;21:812–822. [PubMed]
32. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, et al. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell. 2011 [PMC free article] [PubMed]
33. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Hum Mol Genet. 2009;18:R137–145. [PMC free article] [PubMed]